Bubbles Themes Watchlists Portfolios Universe Today News Alerts Research Articles Bots About

Daily digest

One email a day · alerts + bubble shifts · free during beta.

About Alerts Research Support ♡Disclosures Terms Privacy FR PT API Follow on X

US equities · Daily close · Refreshed nightly 22:30 Paris

Not investment advice. QuantAbundancia is educational research only. Nothing on this site is a recommendation to buy, sell, or hold any security. Past performance does not guarantee future results. Full disclosures.

We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.

News

High-signal headlines only — macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

2,486 signal articles · 204 in last 24h · 10,656 total before filter · latest 33m ago

204last 24h

1888last 7d

375🟢 bullish (7d)

178🔴 bearish (7d)

114publishers

All 🌍 Macro165 📊 Earnings1085 🤝 M&A81 ⚖️ Regulatory23 🚀 Product15 📈 Analyst16

✕ clear all filtersticker: NVAXsentiment: bullishSentiment:bullish neutral bearish ✓ showing all (incl. clickbait)

Zacks1d agobullish

NVAX Q1 Earnings Beat, Stock Jumps 16% on Matrix-M Deal Momentum

Novavax's shares rise 16% after Q1 earnings beat estimates as the company expands Matrix-M partnerships across oncology and infectious diseases.

NVAX PFE

Zacks2d agobullish

Novavax (NVAX) Reports Q1 Loss, Beats Revenue Estimates

Novavax (NVAX) delivered earnings and revenue surprises of +75.68% and +100.70%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

NVAX

StockStory3d agobullish

Novavax (NASDAQ:NVAX) Surprises With Strong Q1 CY2026, Stock Soars

Vaccine biotechnology company Novavax (NASDAQ:NVAX) beat Wall Street’s revenue expectations in Q1 CY2026, but sales fell by 79.1% year on year to $139.5 million. Its GAAP loss of $0.06 per share was 73.5% above analysts’ consensus estimates.

NVAX

Zacks4d agobullish

Are These 5 Biotech Stocks Set to Beat Q1 Earnings Estimates?

ANI Pharmaceuticals, Novavax and three other biotechs show strong Earnings ESP signals, hinting at potential Q1 earnings beat as sector results roll in.

LLY NVAX